G-CSF Market 2026 unlocking new opportunities in hematology

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The G-CSF (Granulocyte Colony Stimulating Factors) Market Over The 2026–2030 Period?

The g-csf (granulocyte colony stimulating factors) market has experienced consistent growth in recent years. Its expansion is projected from $9.48 billion in 2025 to reach $9.94 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 4.8%. Historically, this growth was driven by factors such as the restricted accessibility of g-csf therapies, the increasing occurrence of chemotherapy-induced neutropenia, a growing population of oncology patients, the granting of regulatory approvals for initial g-csf products, and the widespread adoption of injectable formulations.

The market for g-csf (granulocyte colony stimulating factors) is anticipated to experience substantial expansion over the upcoming years, projected to reach $12.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This projected growth is driven by several factors, including the introduction of new g-csf products, the wider availability of biosimilars in developing regions, increased application of combination therapies, a surge in demand for pre-filled syringe formats, and heightened investment in supportive care as well as neutropenia management initiatives. Key trends anticipated during this period encompass a growing preference for g-csf biosimilars, a greater uptake of pre-filled syringes and injectable forms, an increase in combination treatments incorporating other growth factors, broader application of g-csf in oncology and blood disorder therapies, and enhanced recognition of neutropenia management and supportive care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3466&type=smp

What Drivers Are Expected To Influence The G-CSF (Granulocyte Colony Stimulating Factors) Market During The Forecast Period?

The G-CSF (granulocyte colony stimulating factor) market is projected to expand due to the escalating incidence of cancer. Cancer, a serious illness defined by the unchecked growth and proliferation of abnormal cells that can impair bodily functions and result in death, is becoming more widespread. This rise in cancer cases is influenced by factors such as aging populations, changes in lifestyle, and environmental exposures that heighten cancer risk. The G-CSF market addresses this trend by providing essential growth factors that stimulate the production of white blood cells, thereby mitigating the risk of infection and sepsis in cancer patients undergoing chemotherapy. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, documented 354,820 new cancer diagnoses in 2023, which equates to an average of 972 per day and represents an increase of 8,605 compared to 2022. Thus, the increasing prevalence of cancer is a primary driver for the growth of the G-CSF (granulocyte colony stimulating factor) market.

How Is The G-CSF (Granulocyte Colony Stimulating Factors) Market Segmented Across Key Categories?

The g-csf (granulocyte colony stimulating factors) market covered in this report is segmented –

1) By Type: Pegfilgrastim, Lenograstim, Filgrastim, Other Types

2) By Product Form: Tablet, Capsule, Other Product Forms

3) By Application: Oncological Diseases, Blood Disorders, Chronic And Autoimmune Disorders, Other Applications

Subsegments:

1) By Pegfilgrastim: Pre-filled Syringes, Vial Formulations, Biosimilars Of Pegfilgrastim

2) By Lenograstim: Injectable Formulations, Vial Formulations, Combination Therapies

3) By Filgrastim: Injectable Formulations, Pre-filled Syringes, Biosimilars Of Filgrastim

4) By Other Types: Filgrastim-sndz (Biosimilar), Novel G-CSF Products In Development, Combination Therapies With Other Growth Factors

Which Upcoming Trends Are Expected To Influence The G-CSF (Granulocyte Colony Stimulating Factors) Market?

Major companies in the G-CSF (granulocyte colony stimulating factor) market are concentrating on technological advancements within hematopoietic therapies, including the design of dimeric fusion proteins to increase neutrophil production and reduce immunogenicity in long-acting G-CSF treatments. Dimeric fusion protein design involves linking two G-CSF molecules into a single protein to extend its half-life and enhance receptor activation without requiring PEGylation. For instance, in November 2023, Evive Biotech Inc., a Singapore-based biopharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for Ryzneuta (efbemalenograstim alfa), a long-acting biosimilar G-CSF aimed at shortening the duration of neutropenia and febrile neutropenia in adults undergoing cytotoxic chemotherapy. Ryzneuta, a modified recombinant G-CSF, stimulates neutrophil production in the bone marrow, thereby accelerating the recovery of neutrophil counts. Its key characteristics include long-acting administration, compatibility with multiple chemotherapy regimens, and availability in a ready-to-use prefilled syringe. It is utilized for the prophylaxis of chemotherapy-induced neutropenia, stem cell mobilization, and supportive care in immunocompromised patients, providing benefits such as fewer injections, improved adherence, and better overall patient outcomes.

Who Are The Dominant Players Shaping The G-CSF (Granulocyte Colony Stimulating Factors) Market Landscape?

Major companies operating in the g-csf (granulocyte colony stimulating factors) market are Amgen Inc., Coherus Biosciences Inc., Sandoz, Biocon/Mylan, Teva Pharmaceuticals Inc., Chugai Pharma, Intalfarmaco Group, Pfizer, Sun Pharmaceutical Industries Limited, Cipla.

Read the full g-csf (granulocyte colony stimulating factors) market report here:

https://www.thebusinessresearchcompany.com/report/g-csf-global-market-report

Which Region Is Forecast To Lead The G-CSF (Granulocyte Colony Stimulating Factors) Market In Terms Of Market Size?

North America was the largest region in the G-CSF (granulocyte colony-stimulating factors) market in 2025. The regions covered in the g-csf (granulocyte colony stimulating factors) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored G-CSF (Granulocyte Colony Stimulating Factors) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3466&type=smp

Browse Through More Reports Similar to the Global G-CSF (Granulocyte Colony Stimulating Factors) Market 2026, By The Business Research Company

Therapeutic Proteins Market Report 2026

https://www.thebusinessresearchcompany.com/report/therapeutic-proteins-global-market-report

Thyroid Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Biosimilar Market Report 2026

https://www.thebusinessresearchcompany.com/report/biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795